Baxter receives US marketing and distributing rights for TachoSil

Baxter Healthcare and Nycomed have signed an agreement that gives Baxter exclusive rights to market and distribute Nycomed’s TachoSil patch in the US.

TachoSil is a fixed combination of a collagen patch coated with human thrombin and fibrinogen and is used in surgical procedures to seal tissue and control bleeding.

The medical patch is currently available in over 50 markets outside the US including in Europe and Japan.

Ron Lloyd, vice-president and general manager of Baxter BioSurgery, highlighted that TachoSil complemented the company’s current portfolio.

“We look forward to bringing this product into the operating room in the United States through Baxter’s established sales force once it has been cleared by the FDA [US Food and Drug Administration],” he added.

The agreement sees Baxter distribute TachoSil in the US until 2022 while Nycomed will continue to manufacture the product, hold the licence and be responsible for all regulatory filings which are expected later this year.

Baxter has stated its expectation to record a special pre-tax charge of $10 million (five million pounds) for in-process research and development associated transaction as a result of the agreement.

Last month, Baxter Healthcare announced that its Gelfoam Plus Haemostasis Kit had received approval from the FDA.